A newly approved rectal cancer drug could help eligible patients avoid chemo, radiation and surgery

AnaptysBio (ANAB) announced FDA approval for GSK's Jemperli (dostarlimab) to treat locally advanced rectal cancer, based on AZUR-1 trial data. The drug showed significant clinical responses, potentially avoiding chemo, radiation, and surgery. GSK will present full data at ESMO Congress 2026. ANAB manages financial collaborations for Jemperli.

Original reporting
Published Oct 19, 2026, 6:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 6:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefRegulation
Primary signal
$GSK
Bullish
high confidence
Mentioned
$GSK · $ANAB
Relevance
9/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$GSKBullishHigh
01

Why it matters

The approval could drive significant royalty revenue for AnaptysBio and expand GSK's oncology pipeline, potentially boosting both stocks.

02

Market read

Regulatory approval is a primary catalyst that can move both GSK and ANAB stocks sharply.

03

What to watch

Reimbursement negotiations and competition from other PD‑1 blockers may limit upside.

Relevance 9/10Novelty 9/10Timing: pre‑market today (Oct 19, 2026)

Background

The FDA granted accelerated approval for Jemperli (dostarlimab) as a monotherapy for locally advanced rectal cancer, marking the first immunotherapy for this indication.

Company-level read

Ticker impact

$GSKBullishHigh confidence
Context

FDA approval of Jemperli for MSI‑H/dMMR rectal cancer provides a new indication for GSK's immunotherapy.

Expected impact

upward pressure as investors price in future sales from the new indication

Evidence & confidence

First FDA approval for this indication; GSK will capture market share from existing chemo/radiation regimens.

$ANABBullishHigh confidence
Context

AnaptysBio manages the financial collaborations for Jemperli and benefits from royalty streams tied to the new FDA indication.

Expected impact

upward pressure as the market values higher future royalty cash flows

Evidence & confidence

ANAB's business model is directly linked to Jemperli sales; new indication increases royalty base.

Market effects

Strengthens the oncology/immune‑oncology sector and may pressure competitors without similar approvals.

Positive for US and European biotech stocks focused on MSI‑H/dMMR therapies.

Adds to global pipeline momentum for PD‑1 inhibitors.

Counterpoint

If the drug fails to achieve commercial uptake, the hype could reverse quickly.

Key entities

  • GSK

    Global pharmaceutical company developing and commercializing Jemperli.

  • AnaptysBio, Inc.

    Biotech firm managing royalty collaborations for Jemperli.

Related articles

$GSKMed

Nelkarmi gives ALK-positive lung cancer patients a new option after first-line therapy stops working

GSK's Nelkarmi (neladalkib) received FDA accelerated approval for ALK-positive NSCLC patients after prior ALK therapy. Approval based on ALKOVE-1 trial showing 49% tumor shrinkage in Alecensa-only group. GSK acquired Nelkarmi via Nuvalent acquisition. Continued approval contingent on confirmatory trial. ALKAZAR phase 3 trial ongoing for first-line treatment.

$GSKMedAI 8/10

GSK’s $10.6bn Nuvalent bet pays off with second lung cancer drug approval

GSK's Nelkarmi (neladalkib) received FDA approval for treating ALK-positive non-small cell lung cancer, the second drug from its $10.6bn Nuvalent acquisition. The approval was based on trial results showing a 49% response rate. GSK expects significant sales, with forecasts predicting $1.2bn by 2032. Roche's Alecensa is a key competitor. Approval hinges on ongoing Phase III trial results.

$GSKMed

GSK Wins Second Lung Cancer Approval of 2026 as FDA Clears Nelkarmi — BigGo Finance

GSK (GSK) received FDA approval for Nelkarmi, a lung cancer drug, based on Phase 1/2 trial data. The drug targets ALK gene mutations and showed activity against brain metastases. GSK acquired Nelkarmi through its $10.6B Nuvalent deal. Analysts project $1B in 2032 sales, with peak sales estimates of $5B-$7B for GSK's lead Nuvalent drugs. The approval is seen as a validation of GSK's oncology portfolio strategy.

$SMMTMedAI 8/10

FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK

FDA rejected Summit Therapeutics' ivonescimab for lung cancer, citing insufficient benefits. Sellas Life Sciences' cancer vaccine showed 41% reduced death risk in a Phase 3 trial. GSK's Nelkarmi, acquired via Nuvalent buyout, gained FDA approval for lung cancer. AstraZeneca's gefurulimab was approved for myasthenia gravis. Eli Lilly partnered with Stipple Bio for cancer drugs, potentially worth $5.9B. Biogen invested $32M in Trimtech for neurodegenerative disease treatments.

$GSKMed

GSK gets second cancer drug approval from Nuvalent buy

GSK's Nelkarmi (neladalkib) received FDA approval for ALK-positive NSCLC after prior ALK inhibitor treatments. The approval follows GSK's $10.6B acquisition of Nuvalent. Analysts project Nelkarmi, Jideytro, and NVL-330 could generate $5B-$7B in annual sales. Nelkarmi showed a 49% objective response rate in trials. GSK aims to boost revenues to £40B by 2031.